TY - JOUR
T1 - Effect of early use of low-dose aspirin therapy on late-onset preeclampsia
AU - Lan, P.G.
AU - Gillin, A.G.
AU - Pelosi, M.
AU - Tooher, Jane
AU - Sandager, P.
AU - Hyett, Jon
PY - 2019
Y1 - 2019
N2 - Objective: Low-dose aspirin (LDA) therapy has been found to be effective in preventing the development of early-onset preeclampsia. However, its effect on late-onset preeclampsia has not been described. Our study was aimed at determining if LDA therapy prescribed from early in pregnancy modified the severity of late-onset preeclampsia. Materials and methods: A retrospective analysis of all women who were screened for early-onset preeclampsia at 11–13 +6 weeks’ gestation between April 2012 and October 2014 at our institution, and who subsequently developed late-onset preeclampsia. The treatment group consisted of women who were prescribed LDA therapy from early in pregnancy as a result of the screening. The control group consisted of women who did not receive LDA therapy. Results: The aspirin group was associated with earlier delivery at 38.0 (37.5–38.5) weeks’ gestation versus 39.0 (38.7–39.4) weeks’ gestation for the nonaspirin group (p <.01). The aspirin group was also associated with lower absolute birth weight 2851 (2646–3055) versus 3215 (3068–3362) grams in the nonaspirin group (p <.01). However, when normalised for gestational age at delivery, the proportion of foetuses that were small for gestation age (< 10th centile) were not significantly different between the two groups [28% in aspirin group versus 23% in nonaspirin group; p =.62]. No other significant difference was noted. Conclusions: There was no difference in the clinical severity of late-onset preeclampsia between women screened as high risk for early-onset preeclampsia and subsequently prescribed LDA during their pregnancy, compared to women found to be at low risk and not prescribed LDA.
AB - Objective: Low-dose aspirin (LDA) therapy has been found to be effective in preventing the development of early-onset preeclampsia. However, its effect on late-onset preeclampsia has not been described. Our study was aimed at determining if LDA therapy prescribed from early in pregnancy modified the severity of late-onset preeclampsia. Materials and methods: A retrospective analysis of all women who were screened for early-onset preeclampsia at 11–13 +6 weeks’ gestation between April 2012 and October 2014 at our institution, and who subsequently developed late-onset preeclampsia. The treatment group consisted of women who were prescribed LDA therapy from early in pregnancy as a result of the screening. The control group consisted of women who did not receive LDA therapy. Results: The aspirin group was associated with earlier delivery at 38.0 (37.5–38.5) weeks’ gestation versus 39.0 (38.7–39.4) weeks’ gestation for the nonaspirin group (p <.01). The aspirin group was also associated with lower absolute birth weight 2851 (2646–3055) versus 3215 (3068–3362) grams in the nonaspirin group (p <.01). However, when normalised for gestational age at delivery, the proportion of foetuses that were small for gestation age (< 10th centile) were not significantly different between the two groups [28% in aspirin group versus 23% in nonaspirin group; p =.62]. No other significant difference was noted. Conclusions: There was no difference in the clinical severity of late-onset preeclampsia between women screened as high risk for early-onset preeclampsia and subsequently prescribed LDA during their pregnancy, compared to women found to be at low risk and not prescribed LDA.
UR - https://hdl.handle.net/1959.7/uws:66357
U2 - 10.1080/14767058.2018.1427718
DO - 10.1080/14767058.2018.1427718
M3 - Article
SN - 1476-7058
VL - 32
SP - 2137
EP - 2142
JO - Journal of Maternal-Fetal and Neonatal Medicine
JF - Journal of Maternal-Fetal and Neonatal Medicine
IS - 13
ER -